Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia
Autore:
David, SR; Taylor, CC; Kinon, BJ; Breier, A;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co Indianapolis IN USA 46285 Labs, Indianapolis, IN 46285 USA
Titolo Testata:
CLINICAL THERAPEUTICS
fascicolo: 9, volume: 22, anno: 2000,
pagine: 1085 - 1096
SICI:
0149-2918(200009)22:9<1085:TEOORA>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; RECEPTOR OCCUPANCY; CLOZAPINE; PLACEBO; TRIAL; DISORDERS;
Keywords:
olanzapine; prolactin; atypical antipsychotic agents; haloperidol; risperidone;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: David, SR Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Drop Code 1748, Indianapolis, IN 46285 USA Eli Lilly & Co Drop Code 1748 Indianapolis IN USA 46285 6285 USA
Citazione:
S.R. David et al., "The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia", CLIN THER, 22(9), 2000, pp. 1085-1096

Abstract

Background: There is relatively little comparative information on elevations in plasma prolactin level (PRL) with conventional versus novel antipsychotic agents. Objective: This paper examines the comparative effects on PRL of olanzapine, risperidone, and haloperidol based on data from 3 multicenter, double-blind, randomized clinical trials. Magnitude of response, dose dependency, time course, effects of sex and age, and response to switching from haloperidol to olanzapine are assessed. Methods: The effects of olanzapine, risperidone, and haloperidol on PRL were assessed in patients with schizophrenia or related psychoses participating in 3 double-blind clinical trials: (1) a 6-week acute trial comparing olanzapine 5 to 20 mg/d (n = 1336) and haloperidol 5 to 20 mg/d (n = 660), with a 1-year, open-label olanzapine extension for responders; (2) a 54-week study comparing olanzapine 5 to 20 mg/d (n = 21), risperidone 4 to 10 mg/d (n = 21), and haloperidol 5 to 20 mg/d (n = 23) in early illness; and (3) a28-week study comparing olanzapine 10 to 20 mg/d (n = 172) and risperidone4 to 12 mg/d (n = 167). Results: PRL elevations were significantly greater with risperidone than with either olanzapine or haloperidol in study 2, and significantly greater than with olanzapine in study 3 tall, P < 0.0001). PRL elevations were significantly greater with haloperidol than with olanzapine in study 1 (P < 0.001). A dose-response relationship was not consistently confirmed with any of the drug treatments. Risperidone-associated PRL elevations peaked relatively early in treatment. In haloperidol- and risperidone-treated patients, the mean change in PRL was greater in women than in men. PRL decreased significantly when treatment was switched from haloperidol to olanzapine. Conclusions: This side-by-side analysis of 3 independent studies suggests that with the 3 antipsychotic drugs studied, PRL is elevated moderately by olanzapine (mean change, 1-4 ng/mL), intermediately by haloperidol (mean change, approximate to 17 ng/mL), and strongly by risperidone (mean change, 45-80 ng/mL). No consistent dose-response relationship was observed, and thetime course and sex-dependency of the response differed between the 3 agents. Patients with haloperidol-induced hyperprolactinemia may benefit from aswitch to olanzapine. Longterm studies examining the health consequences of chronic hyperprolactinemia during antipsychotic treatment are needed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 10:06:52